Picomolar Detection of Tau Protein Using 1D Photonic Crystal Biochips for Alzheimer's Disease Diagnosis

Picomolar Detection of Tau Protein Using 1D Photonic Crystal Biochips for Alzheimer's Disease Diagnosis

Abstract Alzheimer's disease (AD) is a progressive neurological disorder that gradually impairs all cognitive functions. The diagnosis typically requires a combination of cognitive assessments, neuroimaging techniques, and biomarker analysis. In healthy neurons, Tau protein stabilizes microtubu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Alberto Sinibaldi, Francesco Chiavaioli, Agostino Occhicone, Norbert Danz, Peter Munzert, Francesco Baldini, Ambra Giannetti, Francesco Michelotti
Format:	Article
Language:	English
Published:	Wiley-VCH 2025-05-01
Series:	Advanced Sensor Research
Subjects:	1D photonic crystals Alzheimer's disease biophotonic platform cerebrospinal fluid tau protein
Online Access:	https://doi.org/10.1002/adsr.202400164
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2017-07-01)

Spectral fingerprint of laser emission from rhodamine 6g infused male Indian Peafowl tail feathers
by: Anthony Fiorito, et al.
Published: (2025-07-01)

The concept of biophotonic signaling in the human body and brain: rationale, problems and directions
by: Ganna Nevoit, et al.
Published: (2025-06-01)

Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
by: Marc Suárez‐Calvet, et al.
Published: (2020-11-01)

Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
by: Adam H. Dyer, et al.
Published: (2025-01-01)

Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings Proteína tau hiperfosforilada no líquido cefalorrraqueano de pacientes com doença de Alzheimer e outras demências: resultados preliminares
by: Ana Paula Barbosa Jeronimo Hartmann, et al.
Published: (2004-09-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-05-01)

Silicon Photomultipliers for Deep Tissue Cerenkov Emission Detection During External Beam Radiotherapy
by: Ibrahim Oraiqat, et al.
Published: (2019-01-01)

Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure A<sup>+</sup>T<sup>+</sup> (A<sup>+</sup>T<sub>1</sub><sup>+</sup>) Alzheimer’s Disease
by: Ioanna Tsantzali, et al.
Published: (2024-12-01)

Retinal tau phosphorylation in Alzheimer's disease: A mass spectrometry study
by: Jessica Santiago, et al.
Published: (2025-10-01)

Pixel-Reassigned Spectral-Domain Optical Coherence Tomography
by: En Bo, et al.
Published: (2018-01-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-11-01)

Nano‐Photonic Crystal D‐Shaped Fiber Devices for Label‐Free Biosensing at the Attomolar Limit of Detection
by: Ignacio Del Villar, et al.
Published: (2024-09-01)

Optical signature of retinal Tau fibrillation
by: Zita Salajková, et al.
Published: (2025-03-01)

Exploring Tau-C, Tau-A, and C1M as biomarkers for Parkinson’s disease
by: Meryem Benmarce, et al.
Published: (2025-04-01)

Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
by: Takanobu Ishiguro, et al.
Published: (2024-08-01)

Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
by: Futao Zhou, et al.
Published: (2024-10-01)

Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology
by: Brian Spencer, et al.
Published: (2025-07-01)

Relationship between tau-PET and quantitative susceptibility mapping in atypical Alzheimer’s disease
by: Neha Singh-Reilly, et al.
Published: (2025-07-01)

Interplay Between Aging and Tau Pathology in Alzheimer’s Disease: Mechanisms and Translational Perspectives
by: Mohammed Alrouji, et al.
Published: (2025-06-01)

Toward High-Speed Imaging of Cellular Structures in Rat Colon Using Micro-optical Coherence Tomography
by: Xiaojun Yu, et al.
Published: (2016-01-01)

Enhance Fluorescence Imaging and Remove Motion Artifacts by Combining Pixel Tracking, Interleaved Acquisition, and Temporal Gating
by: Christopher Mela, et al.
Published: (2021-01-01)

Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
by: Annibale Antonioni, et al.
Published: (2025-01-01)

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
by: Branislav Kovacech, et al.
Published: (2024-11-01)

Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model
by: Douglas M. Lopes, et al.
Published: (2024-04-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-07-01)

Estimation of carotinoid, antioxidant, and oxidant statusby biophotonic scanning in healthy and sick persons with risk factorsof atherosclerosis
by: V. N. Kim, et al.
Published: (2007-12-01)

Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models
by: Xiyan Rui, et al.
Published: (2024-12-01)

Traditional Chinese medicine in Alzheimer's disease: From the perspective of GSK-3β and Tau hyperphosphorylation
by: Mei Wang, et al.
Published: (2024-12-01)

Temperature-Dependent Aggregation of Tau Protein Is Attenuated by Native PLGA Nanoparticles Under in vitro Conditions
by: Paul PS, et al.
Published: (2025-02-01)

Tau‐targeting nanoparticles for treatment of Alzheimer's disease
by: Shreya Pawar, et al.
Published: (2025-04-01)

Detecting amyloid and tau pathology in Parkinson’s disease, 4R-tauopathies and control subjects with plasma pTau217
by: Giulia Musso, et al.
Published: (2025-08-01)

Modern biomarkers as key tools in the early diagnosis and monitoring of Alzheimer's disease progression
by: Konrad Strużek, et al.
Published: (2025-04-01)

Advancements in photophysics research and applications of phosphorene semiconductors
by: HUANG Weichun, et al.
Published: (2024-05-01)

Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer’s Disease
by: Alexandra Gogola, et al.
Published: (2025-02-01)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
by: Cassandra Marotta, et al.
Published: (2025-04-01)

Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease
by: Abdolhossein Zare, et al.
Published: (2025-07-01)

Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
by: Divya Bali, et al.
Published: (2025-06-01)

The Role and Pathogenesis of Tau Protein in Alzheimer’s Disease
by: Xiaoyue Hong, et al.
Published: (2025-06-01)